

RESEARCH

Shorter telomeres associated with high doses of glucocorticoids: the link to increased mortality?

Anastasia P Athanasoulia-Kaspar^{1,*}, Matthias K Auer^{1,2,*}, Günter K Stalla¹ and Mira Jakovcevski³

¹Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany

²Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany

³Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany

Correspondence should be addressed to A P Athanasoulia-Kaspar: anastasia.athanasoulia@hotmail.com

*(A P Athanasoulia-Kaspar and M K Auer contributed equally to this work)

Abstract

Objective: Patients with non-functioning pituitary adenomas exhibit high morbidity and mortality rates. Growth hormone deficiency and high doses of glucocorticoid substitution therapy have been identified as corresponding risk factors. Interestingly, high levels of endogenous cortisol in, e.g., patients with post-traumatic stress disorder or patients with Cushing's disease have been linked to shorter telomere length. Telomeres are noncoding DNA regions located at the end of chromosomes consisting of repetitive DNA sequences which shorten with aging and hereby determine cell survival. Therefore, telomere length can serve as a predictor for the onset of disease and mortality in some endocrine disorders (e.g., Cushing's disease).

Design/methods: Here, we examine telomere length from blood in patients ($n = 115$) with non-functioning pituitary adenomas (NFPA) in a cross-sectional case–control ($n = 106$, age-, gender-matched) study using qPCR. Linear regression models were used to identify independent predictors of telomere length.

Results: We show that patients with NFPA exhibited shorter telomeres than controls. No significant association of indices of growth hormone deficiency (IGF-1-level-SDS, years of unsubstituted growth hormone deficiency etc.) with telomere length was detected. Interestingly, linear regression analysis showed that hydrocortisone replacement dosage in patients with adrenal insufficiency ($n = 52$) was a significant predictor for shorter telomere length ($\beta = 0.377$; $P = 0.018$) independent of potential confounders (gender, age, BMI, arterial hypertension, systolic blood pressure, number of antihypertensive drugs, total leukocyte count, waist-to-hip ratio, waist circumference, diabetes mellitus type 2, HbA1c, current statin use). Median split analysis revealed that higher hydrocortisone intake (>20 mg) was associated with significantly shorter telomeres.

Conclusion: These observations strengthen the importance of adjusted glucocorticoid treatment in NFPA patients with respect to morbidity and mortality rates.

Key Words

- ▶ telomere
- ▶ pituitary adenomas
- ▶ glucocorticoid substitution
- ▶ adrenal insufficiency

Endocrine Connections
(2018) 7, 1217–1226

Introduction

Telomeres are noncoding DNA regions located at the end of chromosomes consisting of repetitive DNA sequences. Their primary purpose is to protect the chromosome from

degradation processes and from loss of genetic material during cell division. When telomeres reach a critical short length, cell division is terminated and the corresponding

<https://ec.bioscientifica.com>
<https://doi.org/10.1530/EC-18-0362>

© 2018 The authors
Published by Bioscientifica Ltd



This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).

cells undergo apoptosis (1). Telomerase, the key enzyme relevant for telomeric DNA synthesis and maintenance of telomere length (TL) is differently expressed in different tissue types and its expression levels depend on the status of the cell itself (2, 3, 4, 5). Differential telomerase activity is likely to account for differences in TL in distinct cell types of the human body. Nevertheless, blood TL is used as an easily accessible and well-established surrogate tissue for TL in other cells of the entire organism, especially when analyzing systemic effects of chronic diseases (6).

Typically, TL shortens with aging and shorter telomeres seem to be associated with age-related disease (7) as well as inflammatory states, cardiovascular disease, diabetes mellitus type 2 (DM2), poor lipid profile and high blood pressure (8, 9, 10). Furthermore, a variety of factors such as epigenetic and environmental factors, including life style habits such as diet or smoking can influence and modulate telomerase activity (1).

Apart from the aforementioned conditions, another influential factor concerning TLs is hormones (11). Currently, pituitary tumors such as somatotrophic and corticotrophic adenomas resulting in hormone excess conditions such as acromegaly (12, 13) and Cushing's syndrome (13) have been associated with accelerated telomere shortening (14, 15), suggesting that TL length might be linked to the increased morbidity and mortality observed for both diseases (16, 17).

To the best of our knowledge, studies examining the TL in patients with non-functioning pituitary adenomas (NFPA), characterized by a high incidence of endocrine deficiencies, have not been conducted. However, taking into account that this patient group exhibits an increased morbidity and mortality (18) and the precise underlying mechanisms of this phenomenon have not been fully elucidated so far, TL studies in these patients could be very relevant. The higher morbidity and mortality in patients with NFPA has been attributed to cardiorespiratory and infectious diseases. Even though there is no consensus on predictive factors of mortality, high doses of glucocorticoid substitution therapy and older age at diagnosis are the most consistently identified risk factors associated with increased morbidity and mortality (18, 19). In addition, growth hormone deficiency (GHD) has been linked to mortality, although due to the retrospective character of these studies, there is still a debate if this relationship is causal (20, 21).

In the current study, we examined whether TL is shorter in patients with NFPA compared to controls and if so, how hormonal deficiencies and their replacement respectively affect TL.

Materials and methods

Patients and control group

We included 115 patients with NFPA treated in the Neuroendocrinology Unit of the Max Planck Institute of Psychiatry in Munich. Samples were retrieved from the biobank of the Network of Excellence for Neuroendocrine Tumors Munich (NeoExNET). All patients gave written informed consent and the study was approved by the Ethical Review Board of the Ludwig Maximilian University of Munich. The diagnosis of NFPA was based on clinical and laboratory findings as well as imaging studies and was confirmed by the pathological examination in patients who had undergone surgery. Clinical data, history of medication and comorbidities were collected retrospectively from patients' charts (Table 1).

Evaluation of pituitary function was based on basal measurements of thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and total testosterone (in men) or estradiol (in women). Adrenal insufficiency was documented by ACTH stimulation test or insulin-tolerance test, whereas GHD by insulin-tolerance test or GHRH-arginine test. Additional parameters were assessed after an overnight fasting between 8:00 and 11:30h using routine clinical methods at the local laboratory of the Max Planck Institute of Psychiatry. Insulin-like growth factor 1 (IGF-1) and growth hormone (GH) were measured on the IMMULITE 2000 analyzer (Siemens). In women in the fertile age range, secondary hypogonadism was defined as the combination of low LH/FSH with secondary amenorrhea for at least 1 year. In women in the postmenopausal age range, secondary hypogonadism was documented when LH/FSH were inappropriately low for the postmenopausal age. In men, secondary hypogonadism was defined as a low testosterone level with an inappropriately low LH/FSH. Secondary hypothyroidism was defined as low FT4 combined with an inappropriately low serum TSH. Patients with adrenal insufficiency were treated with conventional hydrocortisone usually divided into 2–3 doses per day. Secondary hypothyroidism was treated with levothyroxine. Gonadotrophic insufficiency was treated with testosterone in men (in form of transdermal gel or intramuscular injections) and with estrogen/progesterone replacement in women or in case of past hysterectomy with estradiol only. GHD was treated with recombinant human GH.

One hundred six controls were selected from a large control group previously recruited for the scope of another study (signed informed consent for the genetic analysis was also obtained from the controls) (22) and

Table 1 Clinical and biochemical characteristics of NFPA patients and controls.

	NFPA patients (n=115)				Controls (n=106)				P
	N (%)		Mean	SDS	N (%)		Mean	SDS	
	Valid	Missing			Valid	Missing			
Age (years)	115	0	57.7	16.76	106	0	58	14.79	NS
Gender (male)	58 (50.4)	0	n.a.	n.a.	58	0	n.a.	n.a.	NS
Body mass index (kg/m ²)	115	0	28.28	5.28	104	0	26.5	4.2	NS
Current smokers	14	10*	n.a.	n.a.	22	6**	n.a.	n.a.	NS
Macroadenoma	111 (96.5)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Pituitary surgery	106 (92.2)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Radiotherapy	17 (14.7)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Diabetes mellitus type 2	12 (10.4)	0	n.a.	n.a.	2 (1.9)	2	n.a.	n.a.	0.011
Fasting glucose (mg/dL)	100	15	86.5	15.63	n.a.	n.a.	n.a.	n.a.	n.a.
HbA1c (%)	94	21	5.53	0.64	n.a.	n.a.	n.a.	n.a.	n.a.
Pituitary insufficiency of any axis	90 (78.3)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
GHD	79 (68.7)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
GHD under substitution	27 (34)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Gonadotropic insufficiency	51 (44.3)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Hypothyroidism	67 (58.3)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Adrenal insufficiency (all under substitution with hydrocortisone)	52	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Diabetes insipidus	18 (15.7)	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Arterial hypertension	45 (39.1)	0	n.a.	n.a.	18 (16.9)	2	n.a.	n.a.	0.001
Systolic blood pressure (mmHg)	108	7	135.74	20.44	n.a.	n.a.	n.a.	n.a.	n.a.
Diastolic blood pressure (mmHg)	108	7	84.95	13.35	n.a.	n.a.	n.a.	n.a.	n.a.
Waist circumference (cm)	85	30	95.69	13.23	n.a.	n.a.	n.a.	n.a.	n.a.
Hip circumference (cm)	78	37	105.5	18.72	n.a.	n.a.	n.a.	n.a.	n.a.
Waist-to-hip-ratio	67	48	1.03	1.08	n.a.	n.a.	n.a.	n.a.	n.a.
Hypercholesterolemia/statin use	31 (27.0)	0	n.a.	n.a.	14 (13.2)	2	n.a.	n.a.	0.016
Triglycerides (mg/dL)	98	17	141.04	80.1	n.a.	n.a.	n.a.	n.a.	n.a.
Total cholesterol (mg/dL)	110	5	209.26	40.69	n.a.	n.a.	n.a.	n.a.	n.a.
HDL cholesterol (mg/dL)	95	20	59.35	18.65	n.a.	n.a.	n.a.	n.a.	n.a.
LDL cholesterol (mg/dL)	94	21	138.95	35.05	n.a.	n.a.	n.a.	n.a.	n.a.
White blood cell count (×10 ⁹ /L)	108	7	6.24	1.35	n.a.	n.a.	n.a.	n.a.	n.a.
IGF-1-SDS (ng/mL)	100	15	136.75	72.99	n.a.	n.a.	n.a.	n.a.	n.a.

GHD, growth hormone deficiency; n.a., non-applicable; NS, non-significant.

*In the NFPA group, 14 current smokers, 32 former smokers and 59 did never smoke; **In the control group, 22 current smokers, 34 former smokers and 44 did never smoke.

were matched for gender and age; the controls did not differ from NFPA patients regarding smoking status that is known to affect TL (Table 1). Furthermore, the presence of anxiety and affective disorders was excluded using the Composite International Diagnostic Screener. Metabolic comorbidities such as hypercholesterinemia, arterial hypertension and DM2 were provided by self-report. For nine patients, no corresponding matching partner could be identified explaining unequal group sizes.

Anthropometric parameters (weight, height, BMI and waist-to-hip ratio) were documented for the majority of the subjects. Hypertension was defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg or previous treatment with antihypertensive medications. DM2 was confirmed by fasting glucose >126 mg/dL in two consecutive measurements or glucose 2 h after an oral tolerance test >200 mg/dL or previous treatment with antidiabetic

medications. Recorded biochemical parameters of lipid metabolism were total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides. Statin medication was noted (Table 1).

TL measurement

TL was assessed in genomic DNA (gDNA), derived from EDTA whole blood. Blood samples were kept at 4°C after blood draw. gDNA from patient and control blood samples was extracted using the Gentra Puregene Blood Kit (Qiagen) and stored at 4°C. Samples were diluted to a concentration of 50 ng/μL and TL was measured by qPCR using a LightCycler FastStart DNA Master SYBR Green kit (Roche Diagnostics) on a LightCycler 96 Instrument (Roche Diagnostics). PCR reactions were run as quadruplicates, split between two different PCR plates with duplicates of each sample on every plate,

pattern was completely at random (26). Five complete datasets were created, to compensate for the uncertainty caused by missing values (27). Subsequently, linear regression modeling was performed on each dataset, and the regression coefficients of the five models were pooled.

Block 1 included gender, age and BMI. A forced entry method was used for block 1 as we deemed inclusion of these variables, according to earlier studies, a basic requirement for our model. In the second block, we added those variables that had been identified in univariate regression analysis as showing a linear correlation at least on trend level ($P < 0.1$) with TL. All statistical tests were performed with $\alpha \leq 0.05$ (two-tailed).

Results

The clinical characteristics of the patients with NFPA and controls are presented in Table 1. In the NFPA group, 111 patients presented with a macroadenoma and 106 had

undergone surgery at least once. The mean time since first diagnosis was 132.8 months (± 86.88). A total of 90 patients (78.3%) presented with pituitary insufficiency of at least one axis (including adrenal, gonadotropic, somatotrophic and thyrotrophic insufficiency or diabetes insipidus). Herein, 79 (68.7%) presented with GHD and 34% of them were under substitution with recombinant human GH; 51 (44.3%) suffered from gonadotropic insufficiency and 67 (58.3%) were hypothyroid (all on levothyroxine replacement), whereas 18 presented with diabetes insipidus and were under substitution with desmopressin and 52 patients were diagnosed with adrenal insufficiency and were under substitution with conventional hydrocortisone.

To investigate whether patients with NFPA exhibit shorter telomeres, we first compared them with age- and gender-matched controls. There were no statistical differences between the two groups regarding ratio of smoking or in terms of BMI compared to controls ($28.28 \text{ kg/m}^2 \pm 5.28$ vs $26.5 \pm 4.2 \text{ kg/m}^2$, $P = 0.07$, Table 1).

Table 2 Univariate correlation analysis of telomere length with clinical and biochemical characteristics of NFPA patients and controls.

Telomere length	NFPA (N = 114)			Controls (N = 106)		
	β	P	N	β	P	N
Age	0.17*	<0.001*	114*	0.08*	0.003*	106*
BMI	0.017	0.167	114	0.012	0.092	106
Gender	0.000	0.896	114	0.005	0.467	106
Current smoking status	0.003	0.556	104	0.001	0.739	100
Diabetes mellitus type 2	0.040*	0.032*	114*	0.015	0.232	104
Fasting glucose	0.020	0.13	99	NA	NA	NA
HbA1c	0.051*	0.04*	83*	NA	NA	NA
Arterial hypertension	0.120*	<0.001*	114*	0.000	0.965	104
Number of antihypertensive drugs	0.130*	<0.001*	114*	NA	NA	NA
Systolic blood pressure	0.060*	0.009*	107*	NA	NA	NA
Diastolic blood pressure	0.006	0.424	107	NA	NA	NA
Waist-to-hip ratio	0.017	0.294	66	NA	NA	NA
Waist circumference	0.030*	0.09*	84*	NA	NA	NA
Total leukocyte count	0.050*	0.03*	107*	NA	NA	NA
Time since diagnosis	0.017	0.255	79	NA	NA	NA
Pituitary insufficiency of any axis	0.014	0.202	114	NA	NA	NA
Overt sex steroid deficiency	0.012*	0.178*	114*	NA	NA	NA
Hypothyroidism	0.005	0.472	114	NA	NA	NA
Overt growth hormone deficiency	0.006	0.412	114	NA	NA	NA
Growth hormone dose	0.020	0.368	36	NA	NA	NA
IGF-1-SDS	0.004	0.526	99	NA	NA	NA
Adrenal insufficiency	0.001	0.731	114	NA	NA	NA
Daily total hydrocortisone dose	0.060*	0.091*	52*	NA	NA	NA
Diabetes insipidus	0.003	0.551	114	NA	NA	NA
Triglycerides	0.008	0.395	97	NA	NA	NA
Current statin use	0.030*	0.079*	114*	NA	NA	NA
Total cholesterol	0.007	0.388	109	NA	NA	NA
HDL cholesterol	0.003	0.580	94	NA	NA	NA
LDL cholesterol	0.002	0.662	93	NA	NA	NA

*Parameters which showed a linear correlation at least on trend level ($P < 0.1$) with telomere length.

However, components of the metabolic syndrome such as hypercholesterolemia (27 vs 13.2%; $P=0.016$), arterial hypertension (39.1 vs 16.3%, $P=0.001$) and DM2 (10.4 vs 1.9%, $P=0.011$) were more common in NFPA patients than in the control population.

We found that patients with NFPA had shorter telomeres compared to controls ($Ct^{Trans} 1.65 \pm 0.22$ vs $Ct^{Trans} 1.56 \pm 0.21$, $P=0.01$). Note, typically, longer telomere templates contain more repeat regions and will create more PCR product in a shorter time, and therefore, lead to lower Ct values in qPCR applications. This difference remained significant when adjusting for hypercholesterolemia, arterial hypertension and DM2 by ANCOVA ($F=5.898$, $df=3$, $P=0.001$).

We conducted an explorative univariate regression analysis to define which variables could influence the TL and found that the following parameters showed a linear correlation at least on trend level ($P<0.1$) with TL: age, DM2, HbA1c, arterial hypertension, number of antihypertensive drugs, systolic blood pressure, waist circumference, total leukocyte count, daily total hydrocortisone dose, current statin use (Table 2). In controls, with regard to available variables, there was only a significant correlation with age. As expected, there was a positive correlation of age with shorter TL in NFPA patients ($\beta=0.17$; $P \leq 0.001$) and controls ($\beta=0.08$, $P=0.003$). As indicated by the higher β -coefficient, telomere shortening seemed to be accelerated in the NFPA group in comparison to controls.

Parameters like BMI, gender, current smoking status, fasting glucose, diastolic blood pressure, waist-to-hip ratio, time since diagnosis, pituitary insufficiency of any axis, HbA1c, overt sex steroid deficiency, hypothyroidism, overt GHD, growth hormone dose, IGF-1, adrenal insufficiency, diabetes insipidus, triglycerides levels, total cholesterol, LDL and HDL cholesterol were not significant and were not included in the regression. The fully adjusted model (Block 2) explained 42.9% of the variance in TL according to the adjusted R^2 (Table 3). In the model, the 'best-fitting' variables were BMI ($\beta=-0.429$; $P=0.015$), number of antihypertensive drugs ($\beta=0.404$; $P=0.014$) and total HC dosage ($\beta=0.377$; $P=0.018$).

Since we identified 'daily total hydrocortisone dose' as a significant independent factor of variance in the regression analysis, we compared patients with adrenal insufficiency with patients with intact corticotrophic axis (Fig. 2). We found that there was no difference regarding TL between patients with and without hydrocortisone substitution. The two groups differ only in terms of basal glucose levels and diastolic blood pressure, but not in terms of BMI, age, white blood cell count, waist circumference

or other parameters such as triglycerides, total cholesterol, HDL or LDL cholesterol or systolic blood pressure. There was no difference between TL of patients with intact GH axis and those with GHD under GH substitution and those with GHD and no treatment of growth hormone (data not shown).

To investigate the effect of hydrocortisone with a focused approach, we conducted a median split analysis in the group of patients with hydrocortisone substitution and we divided patients into two groups, i.e., one with patients who received a total daily hydrocortisone substitution of 20mg or less (Group 1–G1– $n=43$, mean daily hydrocortisone dose 17.39 ± 3.96 mg) and the other one with patients who received a dose higher than 20mg (Group 2–G2– $n=9$, mean daily hydrocortisone dose 27.78 ± 5.07 mg). We found that patients in G2 on the higher hydrocortisone dose exhibited shorter telomeres than in group 1 (G1 $Ct^{Trans} 1.63 \pm 0.21$ vs G2 $Ct^{Trans} 1.82 \pm 0.197$, $P=0.012$). Groups did not differ in fasting blood glucose levels, HbA1c, BMI, white blood cell count, waist-to-hip ratio, waist circumference, age, total cholesterol, HDL/LDL cholesterol, triglycerides, IGF-1-SDS, diastolic or systolic blood pressure.

Discussion

Our initial hypothesis was that patients with NFPA exhibit accelerated telomere shortening due to different pituitary insufficiencies. To test this hypothesis, we compared TL of NFPA patients and controls and examined the influence of different pituitary insufficiencies including adrenal, gonadotropic and somatotropic. Indeed, we could demonstrate that patients with NFPA exhibit shorter telomeres than controls and that telomere shortening per year of age seems to be accelerated in these patients. Interestingly, among patients with pituitary insufficiencies, there was a clear association of higher hydrocortisone doses with shorter TL. To the best of our knowledge, this is the first study to evaluate TL in patients with NFPA.

TL serves as an early predictor of disease onset and all-cause mortality for numerous diseases. Several studies suggest that shorter telomeres are found in patients that exhibit a higher all-cause mortality and TLs appear to reflect the 'ability to survive' (28). Furthermore, short TLs may also be a risk factor for cardiovascular diseases as it is associated with metabolic disturbances such as high blood glucose and greater abdominal obesity, poor lipid profile, high systolic blood pressure, higher fasting glucose levels and smoking (29).

Table 3 Regression analysis of determinants of telomere length in NFPA patients.

Determinant variables	Telomere length (TL)			
	β	P (variable)	Adjusted R^2	P (model)
Block 1			0.22	<0.001
Gender	0.042	0.812		
Age ^b	0.465	0.005		
BMI ^b	-0.224	0.206		
Block 2 ^a			0.429	<0.001
Gender	-0.231	0.2		
Age ^b	0.297	0.051		
BMI ^b	-0.429	0.015		
Number of antihypertensive drugs	0.404	0.014		
Daily total HC dose	0.377	0.018		

Multiple imputation was used to fill in missing values based on the confirmation that the missing pattern was completely at random. Five complete datasets were created, to compensate for the uncertainty caused by missing values. Subsequently, linear regression modeling was performed on each dataset, and the regression coefficients of the five models were pooled.

^aBlock 1 + diabetes mellitus type 2, HbA1c, arterial hypertension, number of antihypertensive drugs, systolic blood pressure, waist circumference, total leucocyte count, current statin use + daily total HC dose; ^blogarithmized.


β , standardized beta coefficient.

Patients with NFPA have higher mortality rates in comparison to the general population, although studies assessing mortality in these patients are limited. Standardized mortality ratios have been reported to be significantly increased in female NFPA patients as compared to male NFPA patients as well as in patients treated with radiotherapy; they are mostly attributed to infectious and cardio/cerebrovascular diseases (30, 31). The role of age at diagnosis as a predictive factor of mortality is discussed controversially. Whereas some studies suggest a positive correlation of age at diagnosis and mortality (32, 33), Olsson *et al.* (2015) come to the opposite conclusion that age of 40 years and earlier is a predictor of mortality (31).

Regarding pituitary hormone deficiencies and their influence on mortality, empirical findings are confounded by differences in the diagnostic and hormone substitution protocols between different study centers over the years. In the present study, we could show that neither somatotrophic nor gonadotrophic deficiency plays any role concerning TL. Taking into consideration that there is a clear link between TL and mortality, our results do not support the association between somatotrophic or gonadotrophic deficiency and higher mortality, either. Indeed, previous data suggest that GH-deficient patients are not at increased risk of death compared to those with intact GH secretion (32, 34). However, concerning gonadotrophic deficiency, data on mortality rates have been inconsistent. According to at least one study, gonadotropin-deficient patients showed higher mortality, an association that remained significant only for men after adjustment for dysfunction of other pituitary axes and sub-analysis of gonadotropin deficiency according to

sex (34). However, Ntali *et al.* (2016) could not confirm that unsubstituted gonadotrophic deficiency poses a risk for mortality.

In the present study, we clearly demonstrated that NFPA patients with adrenal insufficiency under hydrocortisone substitution did not show shorter telomere compared to those with intact corticotrophic axis. Our results are in accordance with data presenting that adrenal deficiency per se is no risk for increased mortality when patients are treated with lower dose (up to 20 mg) of hydrocortisone (19, 32). Here we show, for the first

**Figure 2**

Telomere length in NFPA depends on the dose of glucocorticoid replacement therapy. Correlation of adjusted pPCR values (Ct) with daily total hydrocortisone dose in NFPA patients with adrenal insufficiency ($n=52$). Note, higher Cts are indicative of shorter telomeres. Pearson correlation: $\beta=0.060$, $P=0.091$. Ct, threshold cycle.

time that the dose of daily hydrocortisone substitution is linked to TL in NFPA and that patients with a higher daily hydrocortisone dose (above 20mg) presented with shorter telomeres. Our findings are in agreement with recent data showing increased overall mortality in patients with NFPA on higher glucocorticoid replacement. Mortality risk in the study of Hammarstrand *et al.* (2017) was higher for patients receiving a daily hydrocortisone dose of more than 20mg compared to subjects with daily hydrocortisone doses of ≤ 20 mg, to patients without glucocorticoid replacement and to the general population (35).

Moreover, our results are in accordance with studies that clearly associate hypercortisolism as in Cushing's syndrome with shorter telomeres (14) and demonstrate that patients with active Cushing's syndrome have shorter TL than those patients who underwent successful therapy of hypercortisolism (36). Furthermore, TL has been evaluated in other conditions with increased endogenous cortisol such as chronic stress exposure and post-traumatic stress disorder (37). Shorter TL has been reported for both neuropsychiatric conditions, notwithstanding the influence of their complex interactions with other chronic diseases on telomere dynamics (37).

In line with those *in vivo* findings are studies showing that exposure to high hydrocortisone levels *in vitro* results in a 50% reduction of telomerase activity in T-lymphocytes (38, 39), clearly suggesting a direct effect of cortisol on TL. However, the underlying mechanism of how high hydrocortisone doses induce telomere shortening remains unresolved. Hypercortisolism seems to contribute to premature aging by inducing accelerated telomere shortening, which might be an explanation for persistent high morbidity and other clinical consequences associated with Cushing's disease, even years after successful treatment for hypercortisolism.

This study has a few limitations. On the one hand, our control group was chosen from a bigger collective of controls after excluding patients with anxiety and depression. We addressed this problem by matching patients *post hoc* with the appropriate controls. The two groups were matched for the known possible confounding factors, i.e., age, gender and smoking status. However, presence of metabolic diseases in controls was only available by self-report, and are therefore likely to be underreported. Other confounding factors such as endogenous glucocorticoid exposure could not be excluded in this control group.

As for any cross-sectional study, causality cannot be inferred. Herein, future studies, beyond the scope of this

study, need to address causality using, e.g., cortisol-treated NFPA patient cells. However, the discussed limitations are much more likely to have led to an underestimation of our effect sizes than to create false-positive findings. Finally, it might be of interest to see, if TL in this particular patient group is indeed predictive for increased mortality.

In summary, we demonstrated for the first time a significant difference between the TL of patients with NFPA and controls. Moreover, we showed a clear association of higher hydrocortisone doses with shorter TL in these patients, which further underlines the great importance of a balanced and adjusted glucocorticoid replacement therapy in NFPA patients.

Declaration of interest

M K A has received consultancy fees from Shire and has been reimbursed conference delegate fees, participant fees for educational events and travel expenses by Pfizer, Ipsen and Lilly. A P A-K has been reimbursed conference delegate fees by Pfizer, Novartis and Sandoz. G K S has received consultancy fees and has been reimbursed conference delegate fees, participant fees for educational events and travel expenses from Pfizer, Ipsen, Lilly, Shire, Novartis, Sandoz, NovoNordisk and HRA. M J does not declare any conflict of interest.

Funding

M J was supported by a NARSAD Young Investigator grant of the Brain & Behavior foundation (New York City, NY, USA). This work was supported by Pfizer (grant number WI196186-INSPIRE).

Author contribution statement

M K A and G K S initially conceived the study. M K A, A P A-K and M J planned the study. M K A and M J analyzed data. A P A-K, M K A and M J wrote the paper.

Acknowledgements

The authors thank Dr Sandra Fill for her contribution in collecting the data, Alina Trontsch for managing and storing gDNA samples within the Biobank at the Max Institute of Psychiatry (Munich, Germany) and Prof. Dr Johannes Kaspar for his valuable contribution in improving the manuscript.

References

- Calado RT & Young NS. Telomere diseases. *New England Journal of Medicine* 2009 **361** 2353–2365. (<https://doi.org/10.1056/NEJMr0903373>)
- Lin KW & Yan J. The telomere length dynamic and methods of its assessment. *Journal of Cellular and Molecular Medicine* 2005 **9** 977–989. (<https://doi.org/10.1111/j.1582-4934.2005.tb00395.x>)
- Takubo K, Aida J, Izumiyama-Shimomura N, Ishikawa N, Sawabe M, Kurabayashi R, Shiraishi H, Arai T & Nakamura K. Changes of telomere length with aging. *Geriatrics and Gerontology International* 2010 **10** S197–S206. (<https://doi.org/10.1111/j.1447-0594.2010.00605.x>)
- Aubert G & Lansdorp PM. Telomeres and aging. *Physiological Reviews* 2008 **88** 557–579. (<https://doi.org/10.1152/physrev.00026.2007>)

- 5 Zhu H, Belcher M & van der Harst P. Healthy aging and disease: role for telomere biology? *Clinical Science* 2011 **120** 427–440. (<https://doi.org/10.1042/CS20100385>)
- 6 Friedrich U, Griese E, Schwab M, Fritz P, Thon K and Klotz U. Telomere length in different tissues of elderly patients. *Mechanisms of Ageing and Development* 2000 **119** 89–99. ([https://doi.org/10.1016/S0047-6374\(00\)00173-1](https://doi.org/10.1016/S0047-6374(00)00173-1))
- 7 Mason PJ & Perdigones N. Telomere biology and translational research. *Translational Research* 2013 **162** 333–342. (<https://doi.org/10.1016/j.trsl.2013.08.009>)
- 8 Fuster JJ & Andrés V. Telomere biology and cardiovascular disease. *Circulation Research* 2006 **99** 1167–1180. (<https://doi.org/10.1161/01.RES.0000251281.00845.18>)
- 9 Salpea KD, Talmud PJ, Cooper JA, Maubaret CG, Stephens JW, Abelak K & Humphries SE. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. *Atherosclerosis* 2010 **209** 42–50. (<https://doi.org/10.1016/j.atherosclerosis.2009.09.070>)
- 10 Harte AL, da Silva NF, Miller MA, Cappuccio FP, Kelly A, O'Hare JP, Barnett AH, Al-Daghri NM, Al-Attas O, Alokail M, *et al.* Telomere length attrition, a marker of biological senescence, is inversely correlated with triglycerides and cholesterol in South Asian males with type 2 diabetes mellitus. *Experimental Diabetes Research* 2012; **2012** 895185. (<https://doi.org/10.1155/2012/895185>)
- 11 Bayne S & Liu JP. Hormones and growth factors regulate telomerase activity in ageing and cancer. *Molecular and Cellular Endocrinology* 2005 **240** 11–22. (<https://doi.org/10.1016/j.mce.2005.05.009>)
- 12 Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. *Journal of Clinical Endocrinology and Metabolism* 2008 **93** 61–67. (<https://doi.org/10.1210/jc.2007-1191>)
- 13 Romijn JA. The chronic syndromes after previous treatment of pituitary tumours. *Nature Reviews Endocrinology* 2016 **12** 547–556. (<https://doi.org/10.1038/nrendo.2016.84>)
- 14 Aulinas A, Ramírez MJ, Barahona MJ, Valassi E, Resmini E, Mato E, Santos A, Crespo I, Bell O, Surrallés J, *et al.* Dyslipidemia and chronic inflammation markers are correlated with telomere length shortening in Cushing's syndrome. *PLoS ONE* 2015 **10** e0120185. (<https://doi.org/10.1371/journal.pone.0120185>)
- 15 Matsumoto R, Fukuoka H, Iguchi G, Odake Y, Yoshida K, Bando H, Suda K, Nishizawa H, Takahashi M, Yamada S, *et al.* Accelerated telomere shortening in acromegaly; IGF-I induces telomere shortening and cellular senescence. *PLoS ONE* 2015 **10** e0140189. (<https://doi.org/10.1371/journal.pone.0140189>)
- 16 Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, Galdiero M & Colao A. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. *Pituitary* 2017 **20** 46–62. (<https://doi.org/10.1007/s11102-017-0797-7>)
- 17 Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM & Colao A. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes and Endocrinology* 2016 **4** 611–629. ([https://doi.org/10.1016/S2213-8587\(16\)00086-3](https://doi.org/10.1016/S2213-8587(16)00086-3))
- 18 Tampourlou M, Fountas A, Ntali G & Karavitaki N. Mortality in patients with non-functioning pituitary adenoma. *Pituitary* 2018 **21** 203–207. (<https://doi.org/10.1007/s11102-018-0863-9>)
- 19 Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E & Stettler C. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. *Journal of Clinical Endocrinology and Metabolism* 2012 **97** E1938–E4192. (<https://doi.org/10.1210/jc.2012-2432>)
- 20 Svensson J & Bengtsson BA. Safety aspects of GH replacement. *European Journal of Endocrinology* 2009 **161** S65–S74. (<https://doi.org/10.1530/EJE-09-0287>)
- 21 Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. *Journal of Clinical Endocrinology and Metabolism* 2007 **92** 976–981. (<https://doi.org/10.1210/jc.2006-2112>)
- 22 Lucae S, Salyakina D, Barden N, Harvey M, Gagné B, Labbé M, Binder EB, Uhr M, Paez-Pereda M, Sillaber I, *et al.* P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. *Human Molecular Genetics* 2006 **15** 2438–2445. (<https://doi.org/10.1093/hmg/ddl166>)
- 23 Gil ME & Coetzer TL. Real-time quantitative PCR of telomere length. *Molecular Biotechnology* 2004 **27** 169–172. (<https://doi.org/10.1385/MB:27:2:169>)
- 24 Zanet DL, Saberi S, Oliveira L, Sattha B, Gadawski I & Côté HC. Blood and dried blood spot telomere length measurement by qPCR: assay considerations. *PLoS ONE* 2013 **8** e57787. (<https://doi.org/10.1371/journal.pone.0057787>)
- 25 Visvikis S, Schlenck A & Maurice M. DNA extraction and stability for epidemiological studies. *Clinical Chemistry and Laboratory Medicine* 1998 **36** 551–555. (<https://doi.org/10.1515/CCLM.1998.094>)
- 26 Donders AR, van der Heijden GJ, Stijnen T & Moons KG. Review: a gentle introduction to imputation of missing values. *Journal of Clinical Epidemiology* 2006 **59** 1087–1091. (<https://doi.org/10.1016/j.jclinepi.2006.01.014>)
- 27 Gladitz J. Rubin, Donald B.: Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons, Chichester – New York – Brisbane – Toronto – Singapore 1987, xxx, 258 S., 6 Abb., £ 30.25, ISSN 0271-6232. *Biometrical Journal* 1989 **31** 131–132. (<https://doi.org/10.1002/bimj.4710310118>)
- 28 Cawthon RM, Smith KR, O'Brien E, Sivatchenko A & Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet* 2003 **361** 393–395. ([https://doi.org/10.1016/S0140-6736\(03\)12384-7](https://doi.org/10.1016/S0140-6736(03)12384-7))
- 29 Willeit J, Willeit J, Brandstätter A, Ehlénbach S, Mayr A, Gasperi A, Weger S, Oberhollenzer F, Reindl M, Kronenberg F, *et al.* Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. *Arterio-Sclerosis, Thrombosis, and Vascular Biology* 2010 **30** 1649–1656. (<https://doi.org/10.1161/ATVBAHA.110.205492>)
- 30 Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. *Lancet* 2001 **357** 425–431. ([https://doi.org/10.1016/S0140-6736\(00\)04006-X](https://doi.org/10.1016/S0140-6736(00)04006-X))
- 31 Olsson DS, Nilsson AG, Bryngelsson IL, Trimpou P, Johannsson G & Andersson E. Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study. *Journal of Clinical Endocrinology and Metabolism* 2015 **100** 2651–2658. (<https://doi.org/10.1210/jc.2015-1475>)
- 32 Ntali G, Capatina C, Fazal-Sanderson V, Byrne JV, Cudlip S, Grossman AB, Wass JA & Karavitaki N. Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. *European Journal of Endocrinology* 2016 **174** 137–145. (<https://doi.org/10.1530/EJE-15-0967>)
- 33 Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB & Kunwar S. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. *Journal of Neurosurgery* 2008 **108** 736–745. (<https://doi.org/10.3171/JNS.2008.108.4.0736>)
- 34 O'Reilly MW, Reulen RC, Gupta S, Thompson CA, Dineen R, Goulden EL, Bugg G, Pearce H, Toogood AA, Gittes NJ, *et al.* ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centres. *Clinical Endocrinology* 2016 **85** 748–756. (<https://doi.org/10.1111/cen.13141>)
- 35 Hammarstrand C, Ragnarsson O, Hallén T, Andersson E, Skoglund T, Nilsson AG, Johannsson G & Olsson DS. Higher glucocorticoid replacement doses are associated with increased mortality in patients

- with pituitary adenoma. *European Journal of Endocrinology* 2017 **177** 251–256. (<https://doi.org/10.1530/EJE-17-0340>)
- 36 Aulinas A, Ramírez MJ, Barahona MJ, Valassi E, Resmini E, Mato E, Santos A, Crespo I, Bell O, Surrallés J, *et al.* Telomere length analysis in Cushing's syndrome. *European Journal of Endocrinology* 2014 **171** 21–29. (<https://doi.org/10.1530/EJE-14-0098>)
- 37 Aulinas A, Ramírez MJ, Barahona MJ, Mato E, Bell O, Surrallés J & Webb SM. Telomeres and endocrine dysfunction of the adrenal and GH/IGF-1 axes. *Clinical Endocrinology* 2013 **79** 751–759. (<https://doi.org/10.1111/cen.12310>)
- 38 Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? *Hormones* 2009 **8** 7–22.
- 39 Choi J, Fauci SR & Effros RB. Reduced telomerase activity in human T lymphocytes exposed to cortisol. *Brain, Behavior, and Immunity* 2008 **22** 600–605. (<https://doi.org/10.1016/j.bbi.2007.12.004>)

 Received in final form 27August2018

Accepted 30August2018

Accepted Preprint published online 31August2018